In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

From Iran To The US: From Scientist To Entrepreneur

Interview With Bioniz CEO Nazli Azimi

Executive Summary

California-based Bioniz’s lead candidate for cutaneous T-cell lymphoma has been granted orphan drug designation and expects to begin Phase III trials in the second half of 2021. CEO Nazli Azimi explains the science, which originated from her research in academia, and talks about her entrepreneurial journey.

You may also be interested in...



Snapshot: August Highlights

A selection of articles you might have missed from July 2021, including exclusive interviews with industry leaders and a deep dive into the RNA therapy pipeline. 

Kaiku Health To Build On 2020 Success With Rapid Expansion

With digital therapies and devices seeing widespread adoption in response to lockdown limitations during the COVID-19 pandemic, Kaiku Health is in a strong position to expand its patient monitoring software. CEO Lauri Sippola spoke with In Vivo about the platform and the company’s plans for 2021 and beyond.

Pipeline Watch: Phase III Readouts In Asthma, NASH And More

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

IV124788

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel